EUCTR2004-001224-21-IT进行中（未招募）不适用
A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral ARV to enfuvirtide ENF and to assess resolution or improvement of ARV toxicities in patients with current, historical treatment-limiting toxicity.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV toxicities in patients with current, historical treatment-limiting toxicities - SWITCH TOX studyHIV infectionClassification code 10020161EUCTR2004-001224-21-ESF. Hoffmann-La Roche Ltd300
进行中（未招募）
不适用
A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV toxicities in patients with current, historical treatment-limiting toxicities - SWITCH TOX studyHIV infectionClassification code 10020161EUCTR2004-001224-21-DEF. Hoffmann-La Roche Ltd300
已完成
3 期
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) [M15-741]Parkinson's DiseaseJPRN-jRCT2080224809AbbVie G.K13
进行中（未招募）
1 期
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion studyParkinson's DiseaseEUCTR2018-002144-85-NLAbbVie Deutschland130
已完成
3 期
A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson*s diseaseNL-OMON55829AbbVie Deutschland GmbH & Co. KG6